Suggested remit: To appraise the clinical and cost effectiveness of palopegteriparatide within its marketing authorisation for treating hypoparathyroidism.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
Process STA Standard
ID number 6380

Provisional Schedule

Committee meeting: 1 06 May 2025
Expected publication 16 July 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Ascendis Pharma (palopegteriparatide)
Others Department of Health and Social Care
  NHS England
Patient carer groups Amend
  Butterfly Thyroid Cancer Trust
  British Thyroid Foundation
  Kidney Care UK
  National Kidney Federation
  Parathyroid UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Thyroid UK
Professional groups Association of Anaesthetists
  Association of Surgeons of Great Britain and Ireland
  British Association of Endocrine and Thyroid Surgeons
  British Association of Surgical Oncology
  British Geriatrics Society
  British Society for Haematology
  British Thyroid Association
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Endocrinology
  UK Clinical Pharmacy Association
  UK Kidney Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AAH Pharmaceuticals (alfacalcidol, calcitriol, calcium carbonate, calcium gluconate, teriparatide)
  Accord Healthcare UK (calcium carbonate, calcium gluconate)
  Alliance Healthcare (alfacalcidol, calcitriol)
  Atnahs Pharma UK (calcitriol, chlortalidone, hydrochlorothiazide)
  Aurobindo Pharma (hydrochlorothiazide)
  B.Braun Medical (calcium gluconate)
  Boehringer Ingelheim (hydrochlorothiazide)
  Brown & Burk UK (hydrochlorothiazide)
  Crescent Pharma (alfacalcidol)
  Daiichi Sankyo UK (hydrochlorothiazide)
  Eli Lilly (teriparatide)
  Essential Healthcare (alfacalcidol, calcium carbonate)
  Forum Health Products (calcium carbonate)
  Galderma UK (calcitriol)
  Galen (calcium carbonate)
  Gedeon Richter UK (teriparatide)
  Glenmark Pharmaceuticals (hydrochlorothiazide)
  Grunenthal (calcium carbonate)
  Haleon UK (calcium carbonate)
  HealthAid (calcium carbonate)
  Hameln Pharma (calcium gluconate)
  Internis Pharmaceuticals (calcium carbonate)
  Mylan (calcium carbonate, hydrochlorothiazide)
  Kyowa Kirin (calcium carbonate)
  Medihealth Northern (alfacalcidol, calcitriol, chlortalidone)
  Mylan (bendroflumethiazide, indapamide)
  Morningside Healthcare (chlortalidone)
  Neon Healthcare (alfacalcidol, calcium carbonate)
  Novartis Pharmaceuticals (hydrochlorothiazide)
  Organon Pharma UK (hydrochlorothiazide)
  Pfizer (hydrochlorothiazide)
  Phoenix Healthcare Distribution (alfacalcidol, calcitriol, calcium carbonate)
  Ranbaxy UK (teriparatide)
  Roche Products (calcitriol)
  Sandoz (calcium carbonate)
  Sanofi (hydrochlorothiazide)
  Sigma Pharmaceuticals (alfacalcidol, bendroflumethiazide, calcitriol, chlortalidone, hydrochlorothiazide, indapamide)
  Stirling Anglian Pharmaceuticals (calcium carbonate)
  Strides Pharma (alfacalcidol)
  Takeda UK (calcium carbonate, recombinant human parathyroid hormone)
  Teva UK (calcitriol, teriparatide)
  Theramex (alfacalcidol)
  Thornton and Ross (teriparatide, hydrochlorothiazide)
  TriOn Pharma (alfacalcidol, calcium carbonate)
  Wockhardt UK (chlortalidone, hydrochlorothiazide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Metabolic & Endocrine Disorders Group
  Cochrane Haematology
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
24 September 2024 Invitation to participate
31 May 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
15 March 2024 - 16 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6380
15 March 2024 In progress
09 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual